{"id":46804,"date":"2019-11-21T12:20:35","date_gmt":"2019-11-21T11:20:35","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=46804"},"modified":"2019-11-21T12:20:35","modified_gmt":"2019-11-21T11:20:35","slug":"ucb-pharma-italia-federico-chinni-e-il-nuovo-ad","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/ucb-pharma-italia-federico-chinni-e-il-nuovo-ad\/","title":{"rendered":"UCB Pharma Italy. Federico Chinni is the new CEO"},"content":{"rendered":"

Since 1 November 2019, Federico Chinni is the new CEO of UCB Italia, a biopharmaceutical company that develops innovative solutions for the treatment of serious diseases in the areas of immunology and neurology.<\/p>\n

PharmaStar \u2013 November 20, 2019<\/a><\/p>\n

\u201cIt is a great honor for me to take over the leadership of our branch\u201d \u2013 he declares Federico Chinni<\/strong>. "As \"\"<\/a>UCB Italia, we will have to contribute to the fascinating challenge of 6 global launches in 6 years, a challenge that we can only overcome by working together, with a model based on agility in the decision-making process and on the transversal nature of skills and roles."<\/p>\n

Born in 1971, married, 2 daughters, Federico Chinni graduated in Law from the University of Bologna. He has developed a twenty-year professional career in multinational companies, first in leading companies in the biomedical sector and then, since 2012, in the pharmaceutical sector, where he held managerial roles of increasing responsibility, both nationally and internationally. At UCB since 2018, he served as director of the neurology division until his promotion.<\/p>\n

The appointment of Federico Chinni comes at a particularly positive moment for UCB: \u201cA few days ago the news of the positive opinion of the CHMP on romosozumab and that of the phase III results of bimekizumab, which open up very promising scenarios for affected patients, from fragility fractures and psoriasis, respectively,\u201d comments Chinni.<\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Dal 1\u00b0 novembre 2019, Federico Chinni \u00e8 il nuovo Amministratore Delegato di UCB Italia, azienda biofarmaceutica che sviluppa soluzioni innovative per il trattamento di gravi malattie nelle aree dell’immunologia e della neurologia. PharmaStar – 20 novembre 2019 \u201c\u00c8 per me un grande onore assumere la guida della nostra filiale\u201d \u2013 dichiara Federico Chinni. \u201cCome UCB …<\/p>","protected":false},"author":4,"featured_media":46807,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-46804","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/46804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=46804"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/46804\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/46807"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=46804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=46804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=46804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}